The question asks how to treat a patient with a low Oncotype Dx score, but an estimated risk of recurrence of 20% without chemotherapy. I am presuming the estimated recurrence risk is based on clinical parameters, such as tumor size and grade, independently from the molecular profiling data. If thi...